Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:BridgeBio_Pharma
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focusesOn |
treatment of transthyretin amyloidosis
|
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Jonathan_Fox
|
| gptkbp:headquartersLocation |
gptkb:San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eidos Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:acoramidis
|
| gptkbp:parentCompany |
gptkb:BridgeBio_Pharma
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:EIDX
|
| gptkbp:website |
https://www.eidostx.com/
|
| gptkbp:bfsParent |
gptkb:AG-10
|
| gptkbp:bfsLayer |
6
|